PHN1 Antibody

What is Profilin 1 and what cellular functions does it regulate?

Profilin 1 (PFN1) is a cytoskeletal protein that primarily binds to actin and significantly affects cytoskeleton structure. PFN1 exhibits concentration-dependent effects on actin dynamics: at high concentrations, it prevents actin polymerization, while at low concentrations, it enhances this process . Beyond its cytoskeletal regulation, PFN1 inhibits the formation of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DG) by binding to phosphatidylinositol 4,5-bisphosphate (PIP2) . Additionally, it plays an important role in preventing protein aggregation, specifically inhibiting androgen receptor (AR) and huntingtin (HTT) aggregation, with G-actin binding being essential for its inhibitory effect on AR .

Understanding these diverse functions makes PFN1 antibodies particularly valuable for studying cytoskeletal regulation, signal transduction, and protein aggregation mechanisms in various cellular contexts.

What types of PFN1 antibodies are available for research applications?

Based on available research tools, several types of PFN1 antibodies have been developed for specific research applications. The anti-Profilin 1 (phospho S138) antibody represents a phospho-specific antibody that recognizes PFN1 only when phosphorylated at serine 138 . This antibody is polyclonal, raised in rabbits using a synthetic peptide immunogen corresponding to the phosphorylated S138 region of human PFN1 .

In contrast to phospho-specific antibodies, researchers also utilize antibodies that recognize total PFN1 regardless of phosphorylation status. The distinction between these antibody types is critical when designing experiments to study PFN1 phosphorylation dynamics in cellular processes.

How is phosphorylation at S138 significant for PFN1 function?

The phosphorylation of PFN1 at serine 138 represents an important post-translational modification that likely regulates its binding properties and cellular functions. While the search results don't explicitly detail the specific functional consequences of S138 phosphorylation, the development of a specific antibody against this modification suggests its biological significance . Phosphorylation often serves as a molecular switch that alters protein-protein interactions or enzyme activity.

When designing experiments to study this modification, researchers should consider using phosphatase inhibitors like calyculin A (as shown in the Western blot experiments) to preserve the phosphorylated state of PFN1 . The ability to distinguish between phosphorylated and non-phosphorylated forms enables researchers to investigate how this modification changes under different cellular conditions.

What are the validated applications for anti-PFN1 (phospho S138) antibody?

The anti-PFN1 (phospho S138) antibody (ab215752) has been validated specifically for Western blot (WB) applications with human samples . This validation status is important because it indicates that the antibody has been tested and confirmed to work reliably in this particular application. When designing experiments, researchers should prioritize applications that have been explicitly validated to ensure reliable results.

The antibody has been cited in at least one scientific publication, providing additional confidence in its utility for research applications . While the search results don't specify other applications like immunoprecipitation, immunofluorescence, or ELISA, researchers should consult the primary literature and manufacturer specifications before attempting to use this antibody in these contexts.

What is the optimal protocol for detecting phosphorylated PFN1 in Western blots?

Based on the Western blot protocol described in the search results, the following methodology is recommended for optimal detection of phosphorylated PFN1:

• Sample preparation: Use Jurkat cell lysates stimulated with calyculin A (100nM) for 30 minutes to enhance phosphorylation levels .

• Antibody dilution: Use the anti-PFN1 (phospho S138) antibody at a 1/1000 dilution for Western blot applications .

• Controls: Include appropriate controls such as:

  • Positive control: Jurkat cell lysate stimulated with calyculin A (100nM) for 30 min

  • Specificity control: Jurkat cell lysate with unphosphorylated Profilin 1

For visualizing results, standard enhanced chemiluminescence (ECL) detection systems are appropriate, similar to those used for other antibody applications described in the search results .

How can researchers induce and maintain PFN1 phosphorylation for experimental purposes?

Calyculin A treatment (100nM for 30 minutes) has been demonstrated to effectively induce PFN1 phosphorylation in Jurkat cells . This compound acts as a potent protein phosphatase inhibitor that prevents dephosphorylation, thereby maintaining proteins in their phosphorylated state.

When designing experiments to study PFN1 phosphorylation, researchers should consider:

• Cell type: While Jurkat cells (a human T lymphocyte cell line) have been validated, the phosphorylation pattern may vary in different cell types.

• Treatment duration: The 30-minute treatment period with calyculin A appears optimal, but time-course experiments may reveal different phosphorylation kinetics in other experimental systems.

• Preservation of phosphorylation: Include phosphatase inhibitors in all buffers during cell lysis and sample processing to prevent loss of phosphorylation.

How can researchers verify the specificity of anti-PFN1 (phospho S138) antibody?

Verifying antibody specificity is crucial for ensuring reliable experimental results. For the anti-PFN1 (phospho S138) antibody, the following approaches can confirm specificity:

• Competition assay: As demonstrated in the Western blot results, compare antibody reactivity between phosphorylated samples and samples containing unphosphorylated Profilin 1 . The absence or reduction of signal in the presence of the unphosphorylated competitor demonstrates specificity for the phosphorylated form.

• Phosphatase treatment control: Treat a portion of your samples with lambda phosphatase to remove phosphate groups, which should eliminate reactivity with the phospho-specific antibody while maintaining reactivity with total PFN1 antibodies.

• Peptide competition: Incubate the antibody with the phosphorylated peptide immunogen prior to the primary antibody incubation step. This should block specific binding and reduce or eliminate the signal.

• siRNA knockdown: Reduce PFN1 expression using siRNA and demonstrate reduced antibody reactivity correlating with protein reduction.

What are common pitfalls when working with phospho-specific antibodies like anti-PFN1 (phospho S138)?

When working with phospho-specific antibodies such as the anti-PFN1 (phospho S138) antibody, researchers should be aware of several common challenges:

• Phosphorylation lability: Phosphorylation can be quickly lost due to endogenous phosphatase activity. Always include phosphatase inhibitors in lysis buffers and handle samples quickly and at cold temperatures.

• Low signal issues: Phosphorylation may occur at low stoichiometry, making detection challenging. Consider using enrichment methods like immunoprecipitation prior to Western blotting.

• Specificity concerns: Phospho-epitopes can sometimes be recognized by multiple antibodies. Always validate with appropriate controls as described in section 3.1.

• Batch-to-batch variability: Polyclonal antibodies like the anti-PFN1 (phospho S138) may show some variation between lots. Document lot numbers and maintain consistency within critical experimental series.

• Buffer compatibility: Some buffer components may interfere with antibody binding to phospho-epitopes. Avoid phosphate buffers when working with phospho-specific antibodies.

How should researchers interpret negative results with PFN1 phospho-antibodies?

Negative results with phospho-specific antibodies require careful interpretation. Consider these potential explanations:

• Absence of phosphorylation: The protein may not be phosphorylated under the specific experimental conditions.

• Technical issues: Problems with sample preparation, antibody dilution, incubation conditions, or detection methods can lead to false negatives.

• Epitope masking: Protein-protein interactions or other post-translational modifications may block antibody access to the phosphorylated epitope.

To troubleshoot negative results:

• Verify that the total protein is present using a non-phospho-specific PFN1 antibody

• Include a positive control (e.g., calyculin A-treated Jurkat cells for anti-PFN1 phospho S138)

• Test alternative lysis conditions that may better preserve or expose the phospho-epitope

• Verify the functionality of detection reagents with other antibodies

How can PFN1 phosphorylation studies be integrated with actin dynamics research?

Given PFN1's critical role in actin dynamics, researchers can design experiments that connect phosphorylation status with functional outcomes in cytoskeletal regulation:

• Correlation analysis: Assess PFN1 phosphorylation levels alongside measurements of actin polymerization rates or cytoskeletal organization.

• Phospho-mimetic mutants: Generate S138E (mimics phosphorylation) and S138A (prevents phosphorylation) PFN1 mutants to directly test the functional impact of this modification on actin binding and polymerization.

• Live-cell imaging: Combine phosphorylation analysis with live-cell imaging of actin dynamics using fluorescent actin probes.

• In vitro reconstitution: Perform actin polymerization assays with purified phosphorylated and non-phosphorylated PFN1 to directly measure the impact of this modification on function.

These approaches enable researchers to establish causal relationships between PFN1 phosphorylation and functional outcomes in cytoskeletal regulation, advancing understanding beyond correlative observations.

What methods exist for simultaneously analyzing multiple PFN1 phosphorylation sites?

While the search results focus on the S138 phosphorylation site, PFN1 likely contains multiple phosphorylation sites that may be co-regulated or function independently. Advanced researchers might consider:

• Mass spectrometry approaches: Phospho-proteomics can identify and quantify multiple phosphorylation sites simultaneously, providing a comprehensive profile of PFN1 modifications.

• Multiplexed Western blotting: Sequential probing with different phospho-specific antibodies, using stripping and reprobing techniques between analyses.

• Multi-color immunofluorescence: If compatible antibodies from different host species are available, researchers can simultaneously visualize multiple phosphorylation sites in cellular contexts.

• Proximity ligation assays: These can detect spatial relationships between different phosphorylated residues or between phosphorylated PFN1 and binding partners.

Advanced bioinformatic approaches can then integrate these data to identify patterns of co-regulation and functional relationships between different phosphorylation events.

How does the development of antibodies like anti-PFN1 (phospho S138) compare with antibody development strategies for other research targets?

The development of phospho-specific antibodies involves specialized strategies that can be compared with other antibody development approaches. The anti-PFN1 (phospho S138) antibody was generated using a synthetic peptide immunogen corresponding to the phosphorylated region . This approach shares similarities with methods used to develop other antibodies, such as the FNA1 antibody for influenza neuraminidase:

• Immunogen selection: Both approaches involve careful selection of immunogenic regions, whether a phosphorylated peptide sequence for PFN1 or specific viral protein domains for influenza antibodies .

• Validation strategies: Similar validation principles apply across different antibody targets, including specificity testing, affinity determination, and application-specific validation .

• Epitope mapping: For both types of antibodies, identifying the precise binding epitope is crucial. For phospho-antibodies like anti-PFN1 (phospho S138), the epitope includes a specific modified amino acid, while for viral targets like FNA1, site-directed mutagenesis identified critical binding residues (219, 254, 358, and 388) .

Understanding these parallels in antibody development allows researchers to apply successful strategies across different research areas, enhancing the development of new research tools.